• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

Research Brief on Pyrimidine Derivative 2138283-35-7: 4,6-Dichloro-5-fluoro-2-[(1-methylethyl)thio]-pyrimidine

The pyrimidine derivative with CAS number 2138283-35-7, specifically 4,6-dichloro-5-fluoro-2-[(1-methylethyl)thio]-pyrimidine, has recently emerged as a compound of significant interest in medicinal chemistry and drug discovery. This halogenated thiopyrimidine scaffold demonstrates unique physicochemical properties that make it particularly valuable for pharmaceutical applications, especially in the development of kinase inhibitors and antiviral agents.

Recent studies published in the Journal of Medicinal Chemistry (2023) have highlighted the compound's role as a key intermediate in synthesizing novel Bruton's tyrosine kinase (BTK) inhibitors. The presence of both chloro and fluoro substituents at the 4,5,6-positions, combined with the isopropylthio group at position 2, creates an optimal electronic configuration for selective protein binding. Researchers at Pfizer have utilized this scaffold in their development of next-generation autoimmune disease therapeutics, demonstrating improved selectivity profiles compared to first-generation inhibitors.

In antiviral research, a 2024 study in Antiviral Research revealed that derivatives of 2138283-35-7 show promising activity against RNA-dependent RNA polymerase (RdRp) of emerging flaviviruses. The compound's ability to maintain stability in physiological conditions while exhibiting low cytotoxicity (CC50 > 100 μM in HEK293 cells) makes it particularly attractive for further development. Molecular docking simulations indicate that the fluoro substituent at position 5 plays a critical role in forming hydrogen bonds with conserved residues in the RdRp active site.

The synthetic accessibility of 2138283-35-7 has also been improved through recent methodological advances. A 2023 publication in Organic Process Research & Development described a novel continuous-flow synthesis approach that increases yield to 78% while reducing hazardous waste generation by 40% compared to traditional batch methods. This green chemistry advancement addresses previous scalability challenges associated with this intermediate.

Ongoing clinical trials (Phase I/II) by several biotech firms are investigating prodrug forms of 2138283-35-7 derivatives for oncology applications. Preliminary results suggest these compounds may overcome resistance mechanisms observed with existing pyrimidine-based therapies, particularly in EGFR-mutant non-small cell lung cancer. The unique substitution pattern appears to prevent common mutation-induced steric clashes while maintaining target engagement.

Future research directions highlighted in recent reviews include exploring the compound's potential in PROTAC (proteolysis targeting chimera) development and as a building block for covalent inhibitors. The reactive chloro groups offer convenient handles for further derivatization, while the isopropylthio moiety provides optimal lipophilicity (calculated logP = 2.1) for blood-brain barrier penetration in CNS-targeted therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)